Navigation Links
Registry unveils 'real-world' data on novel excel stent
Date:3/31/2008

CHICAGO, Ill. (March 31, 2008) Real-world use of a novel drug-eluting stent coated with a biodegradable polymer is associated with good clinical outcomes, according to one-year data from a large international registry. Results of the CREATE study, which focused on the sirolimus-eluting Excel stent, are being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

For the study, Yaling Han, MD, Shenyang Northern Hospital, Shenyang, China, and colleagues recruited a total of 2,077 patients from 59 medical centers in four countries. All had stenting with the Excel stent, a novel device with a biodegradable polymer coating. Of these, 369 (17.8 percent) underwent primary stenting within 24 hours of having a heart attack.

After stenting, all patients were prescribed both clopidogrel and aspirin for six months to inhibit the action of platelets in the blood. Anti-platelet medications prevent the development of unwanted blood clots within the stent, or stent thrombosis, a serious complication that can cause heart attack or even death. On average, patients continued to take clopidogrel for 199 days.

Twelve-month follow-up data were available for 2,060 patients (99.2 percent). After 12 months, the overall rate of major cardiovascular complications was 2.77 percent, including cardiac death in 23 patients (1.12 percent), heart attack in 8 patients (0.39 percent), and repeat coronary procedure in 32 patients (1.55 percent). Death from any cause occurred in 34 patients (1.64 percent), including 11 noncardiac deaths. Overall, thrombotic complications occurred in 16 patients (0.78 percent), including six definite cases, five pro
'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
2. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
3. Establishment of Topps Meat Recall Registry for Victims of E. Coli Poisoning
4. E. Coli Registry Expanded for Victims of E. Coli Poisoning from Cargill Ground Beef
5. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
6. Matrix registry probes adherence to clopidogrel at 1 year
7. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
8. Wellcorps International Unveils New Nutritional Supplements
9. The Village Company Unveils Natural Bath and Body Solutions for Everyday Ailments
10. Rice unveils $100 million initiative for world health technology
11. Medco Unveils Three New Medicare Prescription Drug Plan Options for 2008 to Provide Seniors More Choice, Better Value and Specialist Pharmacists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Rising temperatures in ... to spread to shallow waters that are becoming warmer, ... coral reefs, ecologists report. A study of 40 ... shows northward movement by the invasive and poisonous lionfish, ... Administration (NOAA) and the University of North Carolina-Wilmington, who ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... in West Africa is starting to spread faster than ever, the ... of the deadly viral infection were reported in just one week. ... 5,300, with roughly half of those reported in the past three ... now tops 2,600. WHO has estimated that as many as ...
(Date:9/18/2014)... 18, 2014 Limited spots remain at ... Only 100 spots are still available for Becker's ASC ... ASCs on October 23-25, 2014 at the Swissotel Chicago. ... Chief Information Officer Strategy Roundtable on November 4, 2014 ... remain for Becker's Hospital Review Chief Executive Officer Strategy ...
(Date:9/18/2014)... One of the most capable and ... ShandsCair Flight Program’s new EC155 B1, will ... at the Air Medical Transport Conference (AMTC), Sept. 22-24, ... into service ShandsCair EC155 and the Vanderbilt University ... AMTC highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... 18, 2014 It is that time of ... and wellness. Once again, Evensong Spa at ... offering three services at a special $50 rate Oct. 20 ... Marcus Hotels & Resorts , is the only Wisconsin ... Americans to embrace health and wellness by experiencing affordable spa ...
Breaking Medicine News(10 mins):Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Limited Spots Remain at Becker's Upcoming ASC and Hospital Conferences 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3
... drugs, promising drug candidates must pass toxicity tests before ... and Whitehead Institute have developed a cell culture ... prove dramatically cheaper than existing animal tests. This assay ... in the drug development process, making it much more ...
... been able to identify neural signatures of effective, ... and analyze both behavior and brain activity ... a specially designed dual-electroencephalogram (EEG) and the conceptual ... study, The Phi Complex as a Neuromarker of ...
... on schedule to become one of the first major universities ... from its campus. University officials intend to give the ... to adjust to the policy: the ban is scheduled to ... is a health issue, said Mary Alice Serafini, assistant vice ...
... Cancer Institute at Princess Margaret Hospital have successfully proven that ... drug that is triggered by a laser light, a ... a study published today in the Proceedings of the National ... Division of Biophysics and Bioimaging, Joey and Toby Tanenbaum/Brazilian Ball ...
... (Childrens Hospital Boston) and colleagues have identified the cancer ... of childhood. ,'Identifying the cancer stem ... in ERMS will likely lead to new insights into ... explains Dr. Zon. ,Rhabdomyosarcoma (RMS) is an ...
... Rsearchers at the University of Florida, found that self-confidence ... more over a lifetime. Believing in yourself ... the study found. ,People with high opinions ... salaries in middle age than their less confident counterparts, ...
Cached Medicine News:Health News:DNA-damage Test Could Aid Drug Development 2Health News:DNA-damage Test Could Aid Drug Development 3Health News:New Brain Neuromarker May Shed Light on Autism and Schizophrenia 2Health News:New Brain Neuromarker May Shed Light on Autism and Schizophrenia 3Health News:University of Arkansas to Ban Tobacco from Its Campus 2Health News:University of Arkansas to Ban Tobacco from Its Campus 3Health News:Scientists Activate New Cancer Drug Using Light and Oxygen 2Health News:Pediatric Cancer Stem Cell Identified 2Health News:Teenage Self Confidence Can Translate Later into Material Wealth 2Health News:Teenage Self Confidence Can Translate Later into Material Wealth 3
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
(Date:9/18/2014)... Texas , Sept. 18, 2014  Casen Buswell has ... and muscles to harden.  His case is one of only ... the world.  The only hospital in the United ... the world, offering treatment with the dual wave-length laser, is ... San Antonio . Using a laser available in ...
(Date:9/18/2014)... PHILADELPHIA and LONDON ... new era for biopharmaceutical companies. Competition for innovation, ... necessity to keep up with the fast-changing environment ... also influence clinical trials, and clinical trial costs ... effective patient recruitment. Studies conducted by ...
Breaking Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... from a Phase III,clinical trial evaluating the efficacy ... the treatment of postmenopausal osteoporosis were,presented at the ... Annual Meeting. In the non-inferiority study comparing risedronate ... [Actonel(R) (risedronate sodium,tablets)] increases in bone mineral density ...
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: